Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Manifaxine
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Manifaxine (GW320659) is a highly selective neuronal norepinephrine and dopamine reuptake inhibitor developed by GlaxoSmithKline. It was investigated as a small molecule therapy for attention-deficit hyperactivity disorder (ADHD), obesity, and smoking cessation. The drug reached phase II clinical trials but development was discontinued for all indications. Manifaxine acts primarily by inhibiting the reuptake of norepinephrine and dopamine in the central nervous system[1][2][4][6].
- Other names
- manifaxinemanifaxinamanifaxinum
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on Manifaxine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Manifaxine.